The Experts below are selected from a list of 4488 Experts worldwide ranked by ideXlab platform

Ric N Price - One of the best experts on this subject based on the ideXlab platform.

Nicholas J White - One of the best experts on this subject based on the ideXlab platform.

  • diagnosis and treatment of Plasmodium Vivax Malaria
    American Journal of Tropical Medicine and Hygiene, 2016
    Co-Authors: Kevin J Baird, Neena Valecha, Stephan Duparc, Nicholas J White, Ric N Price
    Abstract:

    Abstract The diagnosis and treatment of Plasmodium Vivax Malaria differs from that of Plasmodium falciparum Malaria in fundamentally important ways. This article reviews the guiding principles, practices, and evidence underpinning the diagnosis and treatment of P. Vivax Malaria.

  • management of relapsing Plasmodium Vivax Malaria
    Expert Review of Anti-infective Therapy, 2016
    Co-Authors: Nicholas J White
    Abstract:

    ABSTRACTIntroduction: Relapses are important contributors to illness and morbidity in Plasmodium Vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium Vivax Malaria. A review was conducted with publications in English, French, Portuguese and Spanish using the search terms ‘P. Vivax’ and ‘relapse’.Areas covered: Hypnozoites causing relapses may be activated weeks or months after initial infection. Incidence and temporal patterns of relapse varies geographically. Relapses derive from parasites either genetically similar or different from the primary infection indicating that some derive from previous infections. Malaria illness itself may activate relapse. Primaquine is the only widely available treatment for radical cure. However, it is often not given because of uncertainty over the risks of primaquine induced haemolysis when G6PD deficiency testing is unavailable. Recommended dosing of primaqui...

  • Blood Stage AntiMalarial Efficacy of Primaquine in Plasmodium Vivax Malaria
    The Journal of Infectious Diseases, 1994
    Co-Authors: Sasithon Pukrittayakamee, S. Vanijanonta, Arun Chantra, Ralf Clemens, Nicholas J White
    Abstract:

    The blood stage antiMalarial efficacy of primaquine (0.25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium Vivax Malaria. Most (75%) had at least one Malaria episode previously. Parasite clearance times after primaquine alone (n = 30) were slower than after chloroquine (n = 30) or combined chloroquine-primaquine (n = 25), but all patients had a satisfactory initial therapeutic response. P. Vivax Malaria recurred in 10 (17%) of 60 patients followed for > or = 2 months and Plasmodium falciparum Malaria developed in another 5 (8%) without reexposure to infection. Recurrences occurred or = 5 weeks later, suggesting relapse. Vivax Malaria responds well initially to either primaquine or chloroquine. The blood stage antiMalarial activity of primaquine may mask chloroquine resistance in combined regimens.

Ishag Adam - One of the best experts on this subject based on the ideXlab platform.

  • Severe Plasmodium falciparum and Plasmodium Vivax Malaria among adults at Kassala Hospital, eastern Sudan
    Malaria Journal, 2013
    Co-Authors: Tajeldin M. Abdallah, Mamoun Magzoub, Mohamed T Abdeen, Ikhlas S Ahmed, Hamdan Z. Hamdan, Ishag Adam
    Abstract:

    Background There have been few published reports on severe Plasmodium falciparum and Plasmodium Vivax Malaria among adults in Africa.

  • severe Plasmodium Vivax Malaria among sudanese children at new halfa hospital eastern sudan
    Parasites & Vectors, 2012
    Co-Authors: Hyder M Mahgoub, Gasim I Gasim, Imad R Musa, Ishag Adam
    Abstract:

    Background: There are few published reports on severe Plasmodium Vivax Malaria in Africa. Methods: Clinical pattern/manifestations of severe P. Vivax were described in children admitted at New Halfa Hospital in Sudan between September 2009-December 2011. Results: Eighteen children were admitted at the hospital during the study period with different manifestations of severe P. Vivax Malaria namely: severe anaemia (6, 33.3%), jaundice (5, 27.8%), thrombocytopenia (4, 22.2%), hypotension (3, 16.7%), cerebral Malaria (2, 11.1%), epistaxis (2, 11.1%), renal impairment (1, 5.5%), hypogylcaemia and more than one manifestation (5, 27.8%). By day 2, all patients were asymptomatic, a parasitaemic and had started oral quinine and primaquine. There was no death among these patients Conclusion: Severe P. Vivax Malaria is an existing entity in eastern Sudan. Further studies are required to understand emergence of severe P. Vivax Malaria.

Marcus V G Lacerda - One of the best experts on this subject based on the ideXlab platform.

  • tafenoquine versus primaquine to prevent relapse of Plasmodium Vivax Malaria
    The New England Journal of Medicine, 2019
    Co-Authors: Alejandro Llanoscuentas, Marcus V G Lacerda, Tran Tinh Hien, Ivan Dario Velez, Chayadol Namaiklarp, Maria F Villegas, Wuelton Marcelo Monteiro, Marcelo A M Brito, Monica R F Costa, Raul Chuquiyauri
    Abstract:

    Abstract Background Tafenoquine, a single-dose therapy for Plasmodium Vivax Malaria, has been associated with relapse prevention through the clearance of P. Vivax parasitemia and hypnozoites, terme...

  • single dose tafenoquine to prevent relapse of Plasmodium Vivax Malaria
    The New England Journal of Medicine, 2019
    Co-Authors: Marcus V G Lacerda, Alejandro Llanoscuentas, Raul Chuquiyauri, Srivicha Krudsood, David L Saunders, Rezika Mohammed, Daniel Yilma, Dhelio Batista Pereira, Fe Espino, Martin Casapia
    Abstract:

    Abstract Background Treatment of Plasmodium Vivax Malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatmen...

  • CYP2D6 activity and the risk of recurrence of Plasmodium Vivax Malaria in the Brazilian Amazon: a prospective cohort study.
    Malaria Journal, 2018
    Co-Authors: Larissa W. Brasil, Marcus V G Lacerda, Wuelton Marcelo Monteiro, Fernanda Rodrigues-soares, Ana Beatriz Santoro, Anne C. G. Almeida, Andrea Kuhn, Rajendranath Ramasawmy, Guilherme Suarez-kurtz
    Abstract:

    Background CYP2D6 pathway mediates the activation of primaquine into active metabolite(s) in hepatocytes. CYP2D6 is highly polymorphic, encoding CYP2D6 isoforms with normal, reduced, null or increased activity. It is hypothesized that Plasmodium Vivax Malaria patients with defective CYP2D6 function would be at increased risk for primaquine failure to prevent recurrence. The aim of this study was to investigate the association of CYP2D6 polymorphisms and inferred CYP2D6 phenotypes with Malaria recurrence in patients from the Western Brazilian Amazon, following chloroquine/primaquine combined therapy.

  • are respiratory complications of Plasmodium Vivax Malaria an underestimated problem
    Malaria Journal, 2017
    Co-Authors: Sara Avalos, Wuelton Marcelo Monteiro, Quique Bassat, Andre Alexandre Gomes, Jose Evelio Albornoz Zerpa, Gustavo Fontecha, Andre Siqueira, Maria Gracas Costa Alecrim, Marcus V G Lacerda
    Abstract:

    Respiratory complications are uncommon, but often life-threatening features of Plasmodium Vivax Malaria. This study aimed to estimate the prevalence and lethality associated with such complications among P. Vivax Malaria patients in a tertiary hospital in the Western Brazilian Amazon, and to identify variables associated with severe respiratory complications, intensive care need and death. Medical records from 2009 to 2016 were reviewed aiming to identify all patients diagnosed with P. Vivax Malaria and respiratory complications. Prevalence, lethality and risk factors associated with WHO defined respiratory complications, intensive care need and death were assessed. A total of 587 Vivax Malaria patients were hospitalized during the study period. Thirty (5.1%) developed respiratory complications. Thirteen (43.3%) developed severe respiratory complications, intensive care was required for 12 (40%) patients and 5 (16.6%) died. On admission, anaemia and thrombocytopaenia were common findings, whereas fever was unusual. Patients presented different classes of parasitaemia and six were aparasitaemic on admission. Time to respiratory complications occurred after anti-Malarials administration in 18 (60%) patients and progressed very rapidly. Seventeen patients (56.7%) had comorbidities and/or concomitant conditions, which were significantly associated to higher odds of developing severe respiratory complications, need for intensive care and death (p < 0.05). Respiratory complications were shown to be associated with significant mortality in this population. Patients with comorbidities and/or concomitant conditions require special attention to avoid this potential life-threatening complication.

  • Cardiovascular changes in patients with non-severe Plasmodium Vivax Malaria ☆
    IJC Heart & Vasculature, 2016
    Co-Authors: Aristoteles Comte Alencar-filho, Marcus V G Lacerda, Wuelton Marcelo Monteiro, João Marcos Bemfica Barbosa Ferreira, Jorge L. Salinas, Camila Fabbri, André M. Siqueira, Katashi Okoshi, Marina Politi Okoshi
    Abstract:

    Background Cardiovascular system involvement in patients with Plasmodium Vivax Malaria has been poorly addressed. The aim of this study was to evaluate cardiac structures and function, and serum markers of cardiovascular injury in patients with the non-severe form of Vivax Malaria in Manaus, Amazonas State, Brazil.

Kevin J Baird - One of the best experts on this subject based on the ideXlab platform.